drugset / Trial / NCT06347497

Zonisamide Versus Topiramate in Migraine

NCT06347497

Phase 3 Completed 600 enrolled Kafrelsheikh University
RandomizedParallel-groupDouble-blindTreatment

Summary

Investigators aim to compare the effect of zonisamide versus topiramate in migraine by assessing the absolute reduction in MMD in each group, the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency

Timeline

Start
2024-04-01
Primary completion
2026-04-01
Completion
2026-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Topiramate Small molecule 50 mg
Subject Zonisamide Other / unclassified 50 mg

Indications